RecruitingAdvanced Solid Tumors
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.
Sponsor: Sun Pharma Advanced Research Company Limited
You may qualify if…
- ✓ 1. Willing and able to give written and dated informed consent (or legally acceptable representative/ impartial witness when applicable) and is available for the entire study.
- ✓ 2. Willing and able to comply with the scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions (in the Investigator's opinion), and be accessible for follow-up.
- ✓ 3. Has locally recurrent or metastatic disease (except sarcomas) which has relapsed or progressed following local standard treatment, or for which no standard treatment is available.
- ✓ 4. Has a life expectancy of ≥3 months.
You may not qualify if…
- ✕ 1. Any major surgery, as determined by the Investigator, within 4 weeks of SBO-154 administration.
- ✕ 2. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination.
- ✕ 3. Known or suspected history of significant drug abuse as judged by the Investigator.
- ✕ 4. Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
- ✕ 5. Known or suspected history of excessive intake of alcohol in the 12 months prior to study entry.
- ✕ 6. Positive exclusion tests: urine pregnancy tests (if applicable), serology tests positive for HIV, HCV, HBsAg (unless they are considered subjects with resolved Hepatitis B and C infection).
- ✕ 7. History of any relevant allergy/ hypersensitivity including known immediate or delayed hypersensitivity reaction or idiosyncrasy to biological agents or drug chemically related to SBO-154 or its excipients.
- ✕ 8. Received an investigational agent within 30 days or 5 half-lives- whichever is shorter prior to SBO-154 administration.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07042100 · last updated 2026-07-28